The overall aim of the PregMet 2 Study is to investigate whether metformin prevents late
miscarriages and preterm deliveries in PCOS women treated with metformin from first trimester
of pregnancy to delivery in a large, randomized, controlled, multi-centre trial setting.
The investigators hypothesis is that metformin compared to placebo treatment from the first
trimester to term, reduces the prevalence of late miscarriage (gestational week 13-22) and
preterm birth (gestational week < 37) in PCOS women diagnosed according to Rotterdam 2003
consensus criteria, with singleton pregnancy.